Since its inception, Abeome has committed to improving the discovery mission for therapeutic monoclonal antibodies. Starting with DiSH™ and now with AbeoMouse™, Abeome continues to set new standards in the way valuable monoclonal antibodies are produced and accessed.
Improving the product development cycle for new therapies is a constant challenge for drug discovery researchers. Abeome’s DiSH™ technology enables the rapid detection and production of highly specific monoclonal antibodies. Learn more »
Triple transgenic mouse engineered with enhanced immune response and with the ability for its affinity matured B-cells (Plasmacytes) to display on their surface the antibody each secretes. Learn more »